Insulet Corporation (NASDAQ:PODD) will release its earnings data after the market closes on Thursday, August 3rd. Analysts expect Insulet Corporation to post earnings of ($0.13) per share for the quarter.

Insulet Corporation (NASDAQ:PODD) last released its earnings results on Monday, May 8th. The medical instruments supplier reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.01. The firm had revenue of $101.70 million during the quarter, compared to analyst estimates of $97.73 million. Insulet Corporation had a negative net margin of 6.81% and a negative return on equity of 48.46%. Insulet Corporation’s quarterly revenue was up 25.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.19) EPS. On average, analysts expect Insulet Corporation to post $-0.48 EPS for the current fiscal year and $-0.14 EPS for the next fiscal year.

Insulet Corporation (NASDAQ PODD) traded down 1.39% during trading on Thursday, reaching $52.50. 118,865 shares of the company traded hands. Insulet Corporation has a 12-month low of $30.69 and a 12-month high of $53.90. The firm’s market capitalization is $3.04 billion. The firm’s 50 day moving average price is $49.04 and its 200 day moving average price is $44.30.

In related news, SVP Michael P. Spears acquired 2,500 shares of the firm’s stock in a transaction dated Tuesday, May 16th. The stock was purchased at an average cost of $40.59 per share, with a total value of $101,475.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David A. Lemoine sold 1,524 shares of the business’s stock in a transaction that occurred on Monday, May 1st. The shares were sold at an average price of $43.40, for a total transaction of $66,141.60. The disclosure for this sale can be found here. Insiders have bought 8,080 shares of company stock valued at $317,339 over the last three months. 1.90% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: This article was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/07/27/insulet-corporation-nasdaqpodd-scheduled-to-post-earnings-on-thursday.html.

PODD has been the topic of a number of research reports. Jefferies Group LLC reaffirmed a “buy” rating on shares of Insulet Corporation in a research note on Friday, June 16th. Canaccord Genuity reaffirmed a “hold” rating and set a $42.00 target price on shares of Insulet Corporation in a research note on Friday, May 26th. BidaskClub raised shares of Insulet Corporation from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, June 27th. Cowen and Company reaffirmed a “buy” rating and set a $52.00 target price on shares of Insulet Corporation in a research note on Friday, July 14th. Finally, ValuEngine raised shares of Insulet Corporation from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Eight research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $48.15.

About Insulet Corporation

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Earnings History for Insulet Corporation (NASDAQ:PODD)

Receive News & Ratings for Insulet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Corporation and related companies with MarketBeat.com's FREE daily email newsletter.